Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 1987;60:738-746

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guth, B. D.
Right arrow Articles by Ross, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guth, B. D.
Right arrow Articles by Ross, J., Jr

Circulation Research, Vol 60, 738-746, Copyright © 1987 by American Heart Association


ARTICLES

Mechanism of beneficial effect of beta-adrenergic blockade on exercise- induced myocardial ischemia in conscious dogs

BD Guth, G Heusch, R Seitelberger and J Ross Jr

We examined the importance of decreased heart rate in the beneficial effect of beta-adrenergic blockade on exercise-induced regional myocardial ischemia and contractile dysfunction in conscious dogs with single vessel coronary stenosis (ameroid constrictor). Studies were performed during control treadmill exercise, which produced regional myocardial ischemia (blood flow measured with microspheres) and wall dysfunction (measured using sonomicrometers). A second run was performed after the administration of atenolol (0.3-1.0 mg/kg i.v.), and the reduced heart rate caused by atenolol during early steady-state running was then prevented by atrial pacing during the latter portion of the run. Atenolol reduced the exercise heart rate from 217 +/- 25 beats per minute (SD, n = 9) to 166 +/- 15, and ischemic zone wall thickening during systole improved from 27 +/- 22% of the resting value in the control run to 50 +/- 25% of the resting value in the atenolol run (p less than 0.01). Atrial pacing then increased heart rate to 217 +/- 23 beats per minute, and regional wall thickening deteriorated to 15 +/- 25% of the resting value. Regional subendocardial blood flow in the ischemic zone during atrial pacing with atenolol was slightly less than that observed in the control run, in both ischemic and control zones, indicating no remaining beneficial effect of atenolol when heart rate reduction was eliminated. We conclude that the only significant mechanism for the improvement in exercise-induced ischemia and wall motion produced by atenolol is a reduction in the exercise heart rate.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
Eur Heart JHome page
J.-C. Tardif, P. Ponikowski, T. Kahan, and for the ASSOCIATE study Investigators
Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial
Eur. Heart J., March 1, 2009; 30(5): 540 - 548.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
G. Heusch, A. Skyschally, P. Gres, P. van Caster, D. Schilawa, and R. Schulz
Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction
Eur. Heart J., September 2, 2008; 29(18): 2265 - 2275.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. J. Zoghbi, T. A. Dorfman, and A. E. Iskandrian
The Effects of Medications on Myocardial Perfusion
J. Am. Coll. Cardiol., August 5, 2008; 52(6): 401 - 416.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
J. L. Zamorano
Heart rate management: a therapeutic goal throughout the cardiovascular continuum
Eur. Heart J. Suppl., August 1, 2008; 10(suppl_F): F17 - F21.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
G. Heusch and R. Schulz
The role of heart rate and the benefits of heart rate reduction in acute myocardial ischaemia
Eur. Heart J. Suppl., September 1, 2007; 9(suppl_F): F8 - F14.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. Fox, J. S. Borer, A. J. Camm, N. Danchin, R. Ferrari, J. L. Lopez Sendon, P. G. Steg, J.-C. Tardif, L. Tavazzi, M. Tendera, et al.
Resting Heart Rate in Cardiovascular Disease
J. Am. Coll. Cardiol., August 28, 2007; 50(9): 823 - 830.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. Cook, M. Togni, M. C. Schaub, P. Wenaweser, and O. M. Hess
High heart rate: a cardiovascular risk factor?
Eur. Heart J., October 2, 2006; 27(20): 2387 - 2393.
[Full Text] [PDF]


Home page
Eur Heart JHome page
J.-C. Tardif, I. Ford, M. Tendera, M. G. Bourassa, K. Fox, and for the INITIATIVE Investigators
Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina
Eur. Heart J., December 1, 2005; 26(23): 2529 - 2536.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
J.-C. Tardif
Ivabradine in clinical practice: benefits of If inhibition
Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H29 - H32.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
K. Fox
Future perspectives of If inhibition in various cardiac conditions
Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H33 - H36.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
P. Koepfli, C. A. Wyss, M. Namdar, M. Klainguti, G. K. von Schulthess, T. F. Luscher, and P. A. Kaufmann
{beta}-Adrenergic Blockade and Myocardial Perfusion in Coronary Artery Disease: Differential Effects in Stenotic Versus Remote Myocardial Segments
J. Nucl. Med., October 1, 2004; 45(10): 1626 - 1631.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
X. Monnet, P. Colin, B. Ghaleh, L. Hittinger, J.-F. Giudicelli, and A. Berdeaux
Heart rate reduction during exercise-induced myocardial ischaemia and stunning
Eur. Heart J., April 1, 2004; 25(7): 579 - 586.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
J.P. Vilaine, C. Thollon, N. Villenueve, and J.L. Peglion
Procoralan, a new selective If current inhibitor
Eur. Heart J. Suppl., September 1, 2003; 5(suppl_G): G26 - G35.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
P. Colin, B. Ghaleh, X. Monnet, J. Su, L. Hittinger, J.-F. Giudicelli, and A. Berdeaux
Contributions of heart rate and contractility to myocardial oxygen balance during exercise
Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H676 - H682.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
T Laperche, D Logeart, A Cohen-Solal, and R Gourgon
Potential interests of heart rate lowering drugs
Heart, April 1, 1999; 81(4): 336 - 341.
[Full Text]


Home page
Cardiovasc ResHome page
P. Mulder, V. Richard, F. Bouchart, G. Derumeaux, K. Munter, and C. Thuillez
Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure
Cardiovasc Res, September 1, 1998; 39(3): 600 - 608.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Yamakawa, M. Takeuchi, H. Takaoka, K. Hata, M. Mori, and M. Yokoyama
Negative Chronotropic Effect of ß-Blockade Therapy Reduces Myocardial Oxygen Expenditure for Nonmechanical Work
Circulation, August 1, 1996; 94(3): 340 - 345.
[Abstract] [Full Text]


Home page
CirculationHome page
G. Ferro, C. Duilio, L. Spinelli, G. A. Liucci, F. Mazza, and C. Indolfi
Relation Between Diastolic Perfusion Time and Coronary Artery Stenosis During Stress-Induced Myocardial Ischemia
Circulation, August 1, 1995; 92(3): 342 - 347.
[Abstract] [Full Text]


Home page
CirculationHome page
J. H. Traverse, J. D. Altman, J. Kinn, D. J. Duncker, and R. J. Bache
Effect of ß-Adrenergic Receptor Blockade on Blood Flow to Collateral-Dependent Myocardium During Exercise
Circulation, March 1, 1995; 91(5): 1560 - 1567.
[Abstract] [Full Text]